Buscar resultados de ensayos clínicos
Myopia - 71 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Condición: Pathological Myopia Fecha: 2010-10-06 Intervenciones:
|
Completed |
Nombre del estudio: A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV Condición: Choroid Neovascularization Secondary to Degenerative Myopia Fecha: 2013-03-11 Intervenciones:
|
Completed |
Nombre del estudio: Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD) Condición:
Intervenciones: Drug: Bevacizumab |
Recruiting |
Nombre del estudio: Ocular Discomfort Assessment After Intravitreal Injections Condición:
|
Recruiting |
Nombre del estudio: Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases Condición:
|
Recruiting |
Nombre del estudio: Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization Condición: Choroidal Neovascularization Fecha: 2016-08-21 Intervenciones: Drug: 0.5mg intravitreal ranibizumab Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerla |
Completed |
Nombre del estudio: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Condición:
|
Completed |
Nombre del estudio: VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) Condición: Myopia, Pathological Fecha: 2010-11-26 Intervenciones:
|
Completed |
Nombre del estudio: A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. Condición: Choroidal Neovascularization Secondary to Pathologic Myopia Fecha: 2014-01-09 Intervenciones: Drug: Ranibizumab All patients will receive a single initial intravitreal injection of ranibizumab 0.5 m |